Back
Speaker illustration

undefined undefined undefined

Presentations

Pharmacogenetics of therapy effectiveness for anthracycline-induced cardiotoxicity

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Access
Like
Thumbnail

Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction

Event: Heart Failure 2021

Topic: Cardiotoxicity of Drugs and Other Therapies

Session: ePoster session

Access
Like
Thumbnail

Prognostic value of soluble ST2 biomarker in heart failure patients with obstructive sleep apnea syndrome

Event: EuroHeartCare - ACNAP Congress 2021

Topic: Allied Professions in Cardiovascular Care

Session: ePosters

Access
Like
Thumbnail

Anthracycline-Induced Cardiotoxicity: predictors for risk assessment in women without cardiovascular diseases

Event: ESC Preventive Cardiology 2021

Topic: Biomarkers

Session: Moderated abstracts - Secondary Prevention and Rehabilitation

Access
Like
Thumbnail

Prognostic role of ST2 in heart failure patients with carbohydrate metabolism disorders

Event: Heart Failure 2019

Topic: Pathophysiology

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Access
Like
Thumbnail

Prognostic value of soluble ST2 biomarker in heart failure patients with preserved ejection fraction

Event: ESC Congress 2018

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure – pathophysiology and mechanisms

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources